News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,090 Results
Type
Article (39705)
Company Profile (247)
Press Release (659138)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204172)
Career Advice (2007)
Deals (35419)
Drug Delivery (95)
Drug Development (81046)
Employer Resources (172)
FDA (16183)
Job Trends (14859)
News (345196)
Policy (32540)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49437)
ALS (89)
Alzheimer's disease (1379)
Antibody-drug conjugate (ADC) (126)
Approvals (16185)
Artificial intelligence (256)
Autoimmune disease (22)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (281)
Cancer (2275)
Cardiovascular disease (175)
Career advice (1676)
Career pathing (30)
CAR-T (152)
Cell therapy (427)
Cervical cancer (19)
Clinical research (66011)
Collaboration (838)
Company closure (1)
Compensation (548)
Complete response letters (19)
COVID-19 (2589)
CRISPR (40)
C-suite (245)
Cystic fibrosis (100)
Data (2228)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (272)
Diagnostics (6372)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (100)
Drug shortages (25)
Duchenne muscular dystrophy (94)
Earnings (86698)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112461)
Executive appointments (731)
FDA (17467)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (754)
Gene editing (106)
Generative AI (19)
Gene therapy (306)
GLP-1 (711)
Government (4419)
Grass and pollen (4)
Guidances (81)
Healthcare (18816)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (118)
Indications (29)
Infectious disease (2731)
Inflammatory bowel disease (141)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16511)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (470)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (321)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (309)
MASH (68)
Medical device (13379)
Medtech (13384)
Mergers & acquisitions (19460)
Metabolic disorders (691)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (90)
Neuropsychiatric disorders (27)
Neuroscience (1916)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (367)
Opinion (204)
Ovarian cancer (76)
Pain (88)
Pancreatic cancer (86)
Parkinson's disease (148)
Partnered (21)
Patents (237)
Patient recruitment (112)
Peanut (46)
People (57318)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20567)
Phase II (29069)
Phase III (21655)
Pipeline (1227)
Policy (141)
Postmarket research (2563)
Preclinical (8744)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22294)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (86)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3576)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (43)
The Weekly (29)
Vaccines (691)
Venture capitalists (41)
Weight loss (235)
Women's health (35)
Worklife (16)
Date
Today (114)
Last 7 days (808)
Last 30 days (2715)
Last 365 days (32652)
2025 (10988)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37852)
Australia (6186)
California (6189)
Canada (2032)
China (526)
Colorado (266)
Connecticut (275)
Delaware (150)
Europe (81289)
Florida (916)
Georgia (207)
Idaho (57)
Illinois (540)
India (25)
Indiana (312)
Iowa (11)
Japan (165)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (898)
Massachusetts (4608)
Michigan (220)
Minnesota (394)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (63)
New Jersey (1742)
New Mexico (28)
New York (1762)
North Carolina (975)
North Dakota (8)
Northern California (2709)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1387)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2328)
Tennessee (102)
Texas (921)
United States (23312)
Utah (183)
Virginia (147)
Washington D.C. (63)
Washington State (553)
West Virginia (3)
Wisconsin (55)
699,090 Results for "aerovance inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
April 21, 2025
·
10 min read
Press Releases
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
April 10, 2025
·
11 min read
Press Releases
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
April 29, 2025
·
7 min read
Press Releases
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
April 7, 2025
·
10 min read
Business
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended March 31, 2024, and recent business highlights.
May 13, 2024
·
9 min read
Press Releases
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
November 1, 2024
·
16 min read
Business
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
Aerovate Therapeutics, Inc. today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.
March 6, 2024
·
6 min read
Business
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended December 31, 2023, and recent business highlights.
March 25, 2024
·
11 min read
Genetown
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today presented a poster outlining baseline characteristics from all patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) at the American Thoracic Society (ATS) 2024 International Conference taking place in San Diego, CA.
May 21, 2024
·
7 min read
Drug Development
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension (PAH).
June 17, 2024
·
6 min read
1 of 69,909
Next
